On the one hand, studies have shown that a PTX-CU combination can not only downregulate Bcl-2 (an anti-apoptotic protein) but also upregulate Caspase-3 and Bax (two pro-apoptotic proteins) to promote apoptosis in a synergistic manner, as well as the cancer metastasis markers, including HIF-1α, VEGF, and MMP 2, can be downregulated through treatment of PTX-CU combination to inhibit proliferation and metastasis (Berrak et al., 2016; Quispe-Soto & Calaf, 2016; Yuan et al., 2017; Calaf et al., 2018; Mu et al., 2020; Yan et al., 2020; Zhang et al., 2020). Here, BCL2 is linked to cancer.